On August 19, 2026, Moderna, Inc. (NASDAQ:MRNA) and Merck & Co., Inc. (NYSE:MRK) said that their personalized mRNA cancer vaccine, combined with Merck's Keytruda, met its main goals in a first-ever Phase 3 trial for melanoma. The news sent Moderna shares up as much as 177%, adding $44 billion to its market value, while Merck shares rose more than 12% to an all-time high.
This is the first personalized cancer vaccine to succeed at the late-stage trial level, a milestone Moderna has pursued for years after its Covid-19 vaccine business faded. The stock became the most shorted in the S&P 500.
Does this trial genuinely validate personalized cancer vaccines as a new class of medicine, or is the market's reaction running ahead of data the companies haven't even fully released yet?
Breakthrough Results vs. Unreleased Data: The Moderna Debate
The combination, involving Moderna, Inc. (NASDAQ:MRNA)'s vaccine intismeran autogene and Merck & Co., Inc. (NYSE:MRK)'s Keytruda, extended the time patients lived without their melanoma returning. It reduced the risk of cancer spreading, building on earlier data showing a 49% reduction in recurrence or death risk and a 59% reduction in distant metastasis risk compared with Keytruda alone. Moderna CEO Stéphane Bancel called it validation of "an entirely new class of medicine." TD Cowen ******* ysts called it "a landmark moment" and expect regulatory approval as soon as next year. Even after the surge, Moderna trades at less than a third of its 2021 peak. Rezilient Health's Dr. Danish Nagda argued the platform remains undervalued given the potential to extend the approach to other cancers.
#vaccine #personalized #trial
This is the first personalized cancer vaccine to succeed at the late-stage trial level, a milestone Moderna has pursued for years after its Covid-19 vaccine business faded. The stock became the most shorted in the S&P 500.
Does this trial genuinely validate personalized cancer vaccines as a new class of medicine, or is the market's reaction running ahead of data the companies haven't even fully released yet?
Breakthrough Results vs. Unreleased Data: The Moderna Debate
The combination, involving Moderna, Inc. (NASDAQ:MRNA)'s vaccine intismeran autogene and Merck & Co., Inc. (NYSE:MRK)'s Keytruda, extended the time patients lived without their melanoma returning. It reduced the risk of cancer spreading, building on earlier data showing a 49% reduction in recurrence or death risk and a 59% reduction in distant metastasis risk compared with Keytruda alone. Moderna CEO Stéphane Bancel called it validation of "an entirely new class of medicine." TD Cowen ******* ysts called it "a landmark moment" and expect regulatory approval as soon as next year. Even after the surge, Moderna trades at less than a third of its 2021 peak. Rezilient Health's Dr. Danish Nagda argued the platform remains undervalued given the potential to extend the approach to other cancers.
#vaccine #personalized #trial
1 day ago
